Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

U.S. News

Ranbaxy, GlaxoSmithKline Settle Dispute Over U.S. Patent Covering Valtrex

July 26, 2007

Under an agreement announced today, Indian pharmaceutical company Ranbaxy Laboratories Inc. will be allowed to introduce generic copies of the herpes drug Valtrex in the United States in the latter half of 2009. Ranbaxy will have 180 days of exclusivity to sell the pill here. The arrangement between Ranbaxy and GlaxoSmithKline PLC clears the way for the British drug company to drop the suit it filed in 2003 in a US court to stop Ranbaxy from selling generic copies of Valtrex. GSK's patent on Valtrex is due to expire in the United States and most European countries in 2009. In February, the US Food and Drug Administration approved Ranbaxy's plan to make and market generic Valtrex.

Back to other news for July 2007

Adapted from:
Associated Press
07.26.2007


  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
 
See Also
More HIV News

Tools
 

Advertisement